Drugs / HSK39297
Trials 9 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07363460 Comparator | Nov 2025 → Nov 2027 expected | lupus nephritis | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07616700 Comparator | Aug 2025 → Dec 2026 expected | IgA glomerulonephritis | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK39297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799546 ↗ |
| Route | Oral | “Single or multiple oral doses of HSK39297” NCT06350279 ↗ |